Letters to the Editor

Predictors of Clinical Outcomes in Patients With Stable Coronary Artery Disease

**Predictores de eventos clínicos en pacientes con enfermedad coronaria estable**

To the Editor,

We read the article by Panoulas et al. with great interest, in which the authors reported the similar 1-year clinical outcomes with ‘Overlapping Biodegradable Scaffolds’ and ‘New Generation Everolimus-eluting Stents’. The investigators should be congratulated on this interesting study. Nevertheless, we would like to make some points in addition to the findings of the present article. Although percutaneous coronary intervention (PCI) is one of the most important treatments in stable coronary artery disease (CAD), the COURAGE investigators demonstrated that PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy in patients with stable CAD. Therefore, optimal medical therapy remains the key point in the treatment of stable CAD regardless of PCI and stent type. In this regard, angiographic success and clinical outcomes should be considered as different topics. Biodegradable scaffolds and everolimus-eluting stents may have similar angiographic and procedural success. However, when evaluating clinical outcomes, optimal medical therapy including statins, beta-blockers and angiotensin converting enzyme inhibitors should be taken into consideration beyond revascularization and antiplatelet therapy. In the present study by Panoulas et al., there are no clear data on treatment with optimal medical therapy except antiplatelets. Significant differences in the treatment of these medications may affect prognosis and clinical outcomes independently of PCI and the stent types used.

In conclusion, despite similar angiographic and procedural success, prognostic comparison of biodegradable scaffolds and everolimus-eluting stents requires more comprehensive evaluation. Since optimal medical therapy reduces adverse outcomes independently of PCI in patients with stable CAD, it should be proven that both groups were treated equally with optimal medical therapy including statins, beta-blockers, and angiotensin-converting enzyme inhibitors.

Mehmet Eyuboglu* and Ugur Kucuk

*Department of Cardiology, Avrupa Medicine Center, Karabaglar, Izmir, Turkey

**Department of Cardiology, Gülhane Military Medical Academy, Haydarpasa Training Hospital, Istanbul, Turkey

* Corresponding author: E-mail address: mhmybgl@gmail.com (M. Eyuboglu).

Available online 21 October 2016

REFERENCES


SEE RELATED ARTICLES:

http://dx.doi.org/10.1016/j.rec.2016.04.010

http://dx.doi.org/10.1016/j.rec.2016.08.011

http://dx.doi.org/10.1016/j.rec.2016.07.012

1885-5857/

© 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.